

Cover Story
By Matthew Bin Han Ong
For more than four decades, Steven Rosenberg's work on tumor infiltrating lymphocytes has met with equal measures of skepticism and cheer—but now, as more patients across multiple cancer types respond to cell transfer immunotherapy, researchers are eager to join the movement Rosenberg indisputably leads.
By Jordan Williams
In Brief
Clinical Roundup
Drugs & Targets
Trending Stories
- NIH eliminates the NCI Board of Scientific Advisors
Over its 28 year history, BSA shaped NCI-funded extramural science - Trump administration is removing the mainstays of NCI and the federal government’s cancer program
Peer review, registries, and evidence-based patient information take a big hit - Cyber-iconoclast Vinay Prasad named head of FDA’s CBER
An oncologist, Prasad has criticized accelerated approval, next-gen sequencing, and targeted therapies - George Weiner: Cancer centers are special, as are site visits in CCSG review
- Vinay Prasad, oncologist and Twitter star, locked in debate over precision medicine
- $180M in NCI grants have been terminated by Trump administration, systematic review finds